Detalles de la búsqueda
1.
Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition.
Eur J Nucl Med Mol Imaging
; 50(9): 2621-2635, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37086273
2.
Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy.
Eur J Nucl Med Mol Imaging
; 49(11): 3651-3667, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608703
3.
Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2.
Gynecol Oncol
; 161(3): 668-675, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33752918
4.
Polyclonal BRCA2 mutations following carboplatin treatment confer resistance to the PARP inhibitor rucaparib in a patient with mCRPC: a case report.
BMC Cancer
; 20(1): 215, 2020 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32171277
5.
Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor.
Xenobiotica
; 50(9): 1032-1042, 2020 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-32129697
6.
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib.
Eur Urol
; 83(3): 200-209, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36243543
7.
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Eur Urol
; 84(3): 321-330, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37277275
8.
The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models.
J Immunother
; 45(8): 335-348, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35791438
9.
Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib.
Clin Pharmacokinet
; 61(11): 1477-1493, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36107395
10.
Population pharmacokinetics of rucaparib in patients with advanced ovarian cancer or other solid tumors.
Cancer Chemother Pharmacol
; 89(5): 671-682, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35397664
11.
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study.
Clin Cancer Res
; 27(24): 6677-6686, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34598946
12.
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration.
J Clin Oncol
; 38(32): 3763-3772, 2020 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32795228
13.
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 Study.
Clin Cancer Res
; 26(11): 2487-2496, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32086346
14.
Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Nat Med
; 25(1): 111-118, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478424
15.
Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Clin Lung Cancer
; 19(6): 518-530.e7, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30279111
16.
Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Clin Cancer Res
; 12(22): 6808-16, 2006 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17121902
17.
Inactivation of Capicua drives cancer metastasis.
Nat Genet
; 49(1): 87-96, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27869830
18.
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.
Cancer Discov
; 7(9): 984-998, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28588062
19.
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.
Nat Genet
; 49(12): 1693-1704, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29106415
20.
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.
Nat Commun
; 7: 11815, 2016 06 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27283993